DK3209313T3 - Et ekstrakt fra indigo naturalis og en fremgangsmåde til fremstilling af samme - Google Patents
Et ekstrakt fra indigo naturalis og en fremgangsmåde til fremstilling af samme Download PDFInfo
- Publication number
- DK3209313T3 DK3209313T3 DK16717299.8T DK16717299T DK3209313T3 DK 3209313 T3 DK3209313 T3 DK 3209313T3 DK 16717299 T DK16717299 T DK 16717299T DK 3209313 T3 DK3209313 T3 DK 3209313T3
- Authority
- DK
- Denmark
- Prior art keywords
- extract
- refined extract
- refined
- psoriasis
- indigo
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims description 154
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 title claims description 49
- 238000000034 method Methods 0.000 title claims description 36
- CRDNMYFJWFXOCH-YPKPFQOOSA-N (3z)-3-(3-oxo-1h-indol-2-ylidene)-1h-indol-2-one Chemical compound N/1C2=CC=CC=C2C(=O)C\1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-YPKPFQOOSA-N 0.000 claims description 94
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 90
- 239000000203 mixture Substances 0.000 claims description 54
- VQQVWGVXDIPORV-UHFFFAOYSA-N Tryptanthrine Chemical compound C1=CC=C2C(=O)N3C4=CC=CC=C4C(=O)C3=NC2=C1 VQQVWGVXDIPORV-UHFFFAOYSA-N 0.000 claims description 52
- CRDNMYFJWFXOCH-BUHFOSPRSA-N Couroupitine B Natural products N\1C2=CC=CC=C2C(=O)C/1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-BUHFOSPRSA-N 0.000 claims description 47
- CRDNMYFJWFXOCH-UHFFFAOYSA-N isoindigotin Natural products N1C2=CC=CC=C2C(=O)C1=C1C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-UHFFFAOYSA-N 0.000 claims description 47
- 235000000177 Indigofera tinctoria Nutrition 0.000 claims description 45
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 45
- 229940097275 indigo Drugs 0.000 claims description 42
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 claims description 42
- 239000002904 solvent Substances 0.000 claims description 34
- 201000004681 Psoriasis Diseases 0.000 claims description 28
- 238000005406 washing Methods 0.000 claims description 28
- DXENDDMPDZMHSQ-UHFFFAOYSA-N Candinine Chemical compound C12=NC3=CC=CC=C3C(=O)N1C1=CC=CC=C1C2=C1C(=O)C2=CC=CC=C2N1 DXENDDMPDZMHSQ-UHFFFAOYSA-N 0.000 claims description 24
- 238000001914 filtration Methods 0.000 claims description 24
- 239000000287 crude extract Substances 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 239000000706 filtrate Substances 0.000 claims description 19
- 238000010992 reflux Methods 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 10
- 239000000047 product Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 8
- 201000000849 skin cancer Diseases 0.000 claims description 8
- 208000017520 skin disease Diseases 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000002159 abnormal effect Effects 0.000 claims description 5
- 230000002757 inflammatory effect Effects 0.000 claims description 5
- 230000003780 keratinization Effects 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 230000009759 skin aging Effects 0.000 claims description 5
- 208000010195 Onychomycosis Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 201000005882 tinea unguium Diseases 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 3
- 206010015278 Erythrodermic psoriasis Diseases 0.000 claims description 2
- 206010028703 Nail psoriasis Diseases 0.000 claims description 2
- 206010037575 Pustular psoriasis Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 206010018797 guttate psoriasis Diseases 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims 6
- 206010048768 Dermatosis Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 241001062009 Indigofera Species 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 32
- 238000004128 high performance liquid chromatography Methods 0.000 description 26
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- 239000010075 Qingdai compound Substances 0.000 description 23
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 230000002401 inhibitory effect Effects 0.000 description 14
- 239000002798 polar solvent Substances 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 210000003491 skin Anatomy 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 108010074109 interleukin-22 Proteins 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 241000382362 Persicaria tinctoria Species 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 239000012091 fetal bovine serum Substances 0.000 description 9
- 238000000021 kinase assay Methods 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 241000257673 Strobilanthes cusia Species 0.000 description 7
- 108700012920 TNF Proteins 0.000 description 7
- 239000002537 cosmetic Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 238000008157 ELISA kit Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- -1 for example Chemical compound 0.000 description 6
- 239000012454 non-polar solvent Substances 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 241000334154 Isatis tinctoria Species 0.000 description 5
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 5
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 5
- 210000005069 ears Anatomy 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 210000005087 mononuclear cell Anatomy 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- 238000002137 ultrasound extraction Methods 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 3
- 244000283207 Indigofera tinctoria Species 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108010000837 Janus Kinase 1 Proteins 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229960002311 dithranol Drugs 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 230000002390 hyperplastic effect Effects 0.000 description 3
- COHYTHOBJLSHDF-BUHFOSPRSA-N indigo dye Chemical compound N\1C2=CC=CC=C2C(=O)C/1=C1/C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-BUHFOSPRSA-N 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 3
- 229940011051 isopropyl acetate Drugs 0.000 description 3
- GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 201000005962 mycosis fungoides Diseases 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 238000001126 phototherapy Methods 0.000 description 3
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 3
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- 208000011733 vascular alteration Diseases 0.000 description 3
- 230000004869 vascular alteration Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 238000003734 CellTiter-Glo Luminescent Cell Viability Assay Methods 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 2
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 108010008165 Etanercept Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 102000000646 Interleukin-3 Human genes 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 239000012901 Milli-Q water Substances 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 208000005141 Otitis Diseases 0.000 description 2
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 2
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 2
- 208000009621 actinic keratosis Diseases 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 2
- 239000012997 ficoll-paque Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000011874 heated mixture Substances 0.000 description 2
- 102000052611 human IL6 Human genes 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 210000004986 primary T-cell Anatomy 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000009121 systemic therapy Methods 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FTZIQBGFCYJWKA-UHFFFAOYSA-N 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 FTZIQBGFCYJWKA-UHFFFAOYSA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- VEIPDPYFJUUBOQ-WOPPDYDQSA-N 5-fluoro-1-[(2r,3s,4s,5r)-4-hydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]pyrimidine-2,4-dione Chemical compound C[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 VEIPDPYFJUUBOQ-WOPPDYDQSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000013165 Bowen disease Diseases 0.000 description 1
- 208000019337 Bowen disease of the skin Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- 102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028999 High mobility group protein HMGI-C Human genes 0.000 description 1
- 101000868333 Homo sapiens Cyclin-dependent kinase 1 Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101000986379 Homo sapiens High mobility group protein HMGI-C Proteins 0.000 description 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101001010626 Homo sapiens Interleukin-22 Proteins 0.000 description 1
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000042838 JAK family Human genes 0.000 description 1
- 108091082332 JAK family Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033554 Palmoplantar keratoderma Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108010001441 Phosphopeptides Proteins 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
- 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 241000545405 Tripterygium Species 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 229960002459 alefacept Drugs 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- ASLUCFFROXVMFL-UHFFFAOYSA-N andrographolide Natural products CC1(CO)C(O)CCC2(C)C(CC=C3/C(O)OCC3=O)C(=C)CCC12 ASLUCFFROXVMFL-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 239000011280 coal tar Substances 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000007905 drug manufacturing Methods 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 239000002035 hexane extract Substances 0.000 description 1
- 238000010842 high-capacity cDNA reverse transcription kit Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 102000056838 human CDK1 Human genes 0.000 description 1
- 102000046157 human CSF2 Human genes 0.000 description 1
- 102000055276 human IL3 Human genes 0.000 description 1
- 102000049918 human JAK1 Human genes 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000003331 infrared imaging Methods 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002843 lactate dehydrogenase assay Methods 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 201000008743 palmoplantar keratosis Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229940112971 protopic Drugs 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000003571 reporter gene assay Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 229940036234 tazorac Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/31—Extraction of the material involving untreated material, e.g. fruit juice or sap obtained from fresh plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Birds (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Packages (AREA)
Claims (13)
1. Fremgangsmåde til fremstilling af et raffineret ekstrakt fra Indigo Naturalis omfattende trinnene: a) at ekstrahere Indigo Naturalis med ethanol under tilbageløb mellem 2 og 8 timer, b) at filtrere blandingen ved en temperatur ikke lavere end 65 °C for at opnå et filtrat, c) at koncentrere filtratet for at opnå et råekstrakt, hvor nævnte råekstrakt eventuelt filtreres (med tilsætning af vand) for at fuldkommen fjerne solventet og de sidste bestanddele stadig til stede i solventet, og tørres, d) (i) at vaske råekstraktet med hexan ved en temperatur ikke lavere end 50 °C mellem 15 og 60 min, (ii) at filtrere blandingen opnået i trin d) (i) ved stuetemperatur for at opnå et produkt, eventuelt at rense det med ethanol og vand (iii) at vaske produktet opnået i trin d) (ii) med ethanol under tilbageløb, og e) at filtrere vaskeblandingen opnået i trin d) ved stuetemperatur og at tørre det resulterende produkt ved en temperatur lavere end 80 °C for at opnå et ekstrakt, der er eventuelt mikroniseret.
2. Fremgangsmåden ifølge krav 1, hvor et mikroniseringstrin udføres efter trin e), for derved at tilvejebringe et raffineret ekstrakt med en partikelstørrelse mellem 25 og 35 pm, fortrinsvis på omkring 30 pm.
3. Raffineret ekstrakt opnåeligt med fremgangsmåden ifølge krav 1 eller 2.
4. Det raffinerede ekstrakt ifølge krav 3, omfattende indirubin som en bestanddel, og eventuelt en eller flere af indigo, tryptanthrin og qingdainon.
5. Det raffinerede ekstrakt ifølge krav 3, omfattende indirubin som en bestanddel i en mængde på mindst 65 % (w/w) af det raffinerede ekstrakt, fortrinsvis 65-90 % (w/w) af det raffinerede ekstrakt.
6. Det raffinerede ekstrakt ifølge kravene 4 eller 5, yderligere omfattende indigo som en bestanddel, fortrinsvis i en mængde på 0,1-15 % (w/w) af det raffinerede ekstrakt.
7. Det raffinerede ekstrakt ifølge et hvilket som helst af kravene 4 til 6, yderligere omfattende tryptanthrin som en bestanddel, fortrinsvis i en mængde på 0,1-5 % (w/w) af det raffinerede ekstrakt.
8. Det raffinerede ekstrakt ifølge et hvilket som helst af kravene 4 til 7, yderligere omfattende qingdainon som en bestanddel, fortrinsvis i en mængde på 0,1-5 % (w/w) af det raffinerede ekstrakt.
9. Det raffinerede ekstrakt ifølge et hvilket som helst af kravene 4 til 8, hvor to eller flere af bestanddelene af indirubin, indigo, tryptanthrin og qingdainon, er i en mængde på 90-99 % (w/w) af det raffinerede ekstrakt.
10. Farmaceutisk sammensætning omfattende det raffinerede ekstrakt ifølge et hvilket som helst af kravene 3 til 9 og en farmaceutisk acceptabel bærer.
11. Raffineret ekstrakt ifølge et hvilket som helst af kravene 3 til 9 til anvendelse i behandlingen af en sygdom eller lidelse valgt fra gruppen bestående af psoriasis, inflammatoriske hudlidelser, onychomykose, hudkræft, unormal keratiniseringsinducerede sygdomme, hudældning, pustulardermatose, og CTCL.
12. Det raffinerede ekstrakt til anvendelse ifølge krav 11, hvor behandlingen afen sygdom eller lidelse er behandlingen af psoriasis.
13. Det raffinerede ekstrakt til anvendelse ifølge krav 12, hvor psoriasissen er kronisk plaque psoriasis, guttat psoriasis, erythrodermisk psoriasis, pustuløs psoriasis, invers psoriasis, neglepsoriasis, og/eller psoriasisgigt.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15163060 | 2015-04-09 | ||
| PCT/EP2016/057761 WO2016162484A1 (en) | 2015-04-09 | 2016-04-08 | An extract from indigo naturalis and a process for preparing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3209313T3 true DK3209313T3 (da) | 2019-02-25 |
Family
ID=52874982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16717299.8T DK3209313T3 (da) | 2015-04-09 | 2016-04-08 | Et ekstrakt fra indigo naturalis og en fremgangsmåde til fremstilling af samme |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US9861673B2 (da) |
| EP (2) | EP3209313B1 (da) |
| JP (1) | JP6820273B2 (da) |
| KR (1) | KR20170133497A (da) |
| CN (1) | CN107427545A (da) |
| AU (1) | AU2016245203B2 (da) |
| BR (1) | BR112017021191B1 (da) |
| CA (1) | CA2981624A1 (da) |
| CY (1) | CY1121187T1 (da) |
| DK (1) | DK3209313T3 (da) |
| ES (1) | ES2709359T3 (da) |
| HR (1) | HRP20190088T1 (da) |
| HU (1) | HUE041308T2 (da) |
| LT (1) | LT3209313T (da) |
| MX (1) | MX378168B (da) |
| PL (1) | PL3209313T3 (da) |
| PT (1) | PT3209313T (da) |
| RS (1) | RS58304B1 (da) |
| SI (1) | SI3209313T1 (da) |
| SM (1) | SMT201900054T1 (da) |
| TR (1) | TR201901146T4 (da) |
| TW (1) | TWI732754B (da) |
| WO (1) | WO2016162484A1 (da) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3280428A1 (en) | 2015-04-09 | 2018-02-14 | Galderma S.A. | Antibacterial indigo naturalis or indigo-producing plant extract and use thereof |
| KR20170133497A (ko) | 2015-04-09 | 2017-12-05 | 갈데르마 소시에떼아노님 | 인디고 내추럴리스로부터의 추출물 및 그의 제조 방법 |
| BR112017021190B1 (pt) | 2015-04-09 | 2021-12-21 | Galderma Sa. | Uso de uma composição farmacêutica que compreende um extrato de indigo naturalis |
| US20200009210A1 (en) * | 2016-12-20 | 2020-01-09 | Seoul National University Hospital | Pharmaceutical Composition Comprising Indigo Pulverata Levis Extract or Fraction Thereof as Effective Ingredient for Preventing or Treating Inflammatory Bowel Disease |
| KR20210150829A (ko) | 2020-06-04 | 2021-12-13 | 경성대학교 산학협력단 | 참당귀 추출물 및 인디루빈 농축물을 포함하는 건선 또는 비염치료용 조성물 |
| CN113009035B (zh) * | 2021-03-04 | 2022-08-02 | 福建卫生职业技术学院 | 基于目标成分敲出的中药药效组分辨识的方法及应用 |
| CN113101879A (zh) * | 2021-03-29 | 2021-07-13 | 李健昕 | 一种板蓝根挥发油微胶囊的制备 |
| KR102861223B1 (ko) * | 2022-02-10 | 2025-09-17 | 동의대학교 산학협력단 | 청대를 유효성분으로 포함하는 암 성장 또는 암 전이 억제용 조성물 |
| WO2023170714A1 (en) * | 2022-03-10 | 2023-09-14 | Joy Vadakkan Thomas | A topical herbal composition for fungal infection, scaling, foot cracking, eczema and dry skin diseases |
| GB202306158D0 (en) | 2023-04-26 | 2023-06-07 | Givaudan Sa | Process |
| CN117269380A (zh) * | 2023-08-18 | 2023-12-22 | 复旦大学 | 一种高效萃取大气膜样品中有机组分的方法 |
| CN120131870A (zh) * | 2023-12-11 | 2025-06-13 | 华药君康有限公司 | 一种治疗银屑病的中药组合物及其制备方法和用途 |
| JP7852835B2 (ja) * | 2024-10-04 | 2026-04-28 | 純 山本 | 藍染方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02264727A (ja) * | 1989-04-04 | 1990-10-29 | Ichimaru Pharcos Co Ltd | 植物抽出物からなる過酸化脂質生成抑制剤 |
| US6524625B2 (en) | 1998-06-30 | 2003-02-25 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyuto | Physiologically active extract obtained from indigo plant polygonum tinctorium |
| DE50008328D1 (de) | 1999-04-14 | 2004-11-25 | Max Zeller & Soehne Ag Romansh | ARZNEIMITTEL ZUR HEMMUNG DES NF-kB TRANSKRIPTIONSFAKTORS |
| CN1317322A (zh) | 2000-04-11 | 2001-10-17 | 汤仪 | 炎疣液 |
| JP5452827B2 (ja) | 2000-10-30 | 2014-03-26 | 株式会社ファンケル | 皮膚賦活用組成物 |
| US20030054047A1 (en) | 2001-06-15 | 2003-03-20 | Sanjiu Medical & Pharmaceutical Co., Ltd. | Pharmaceutical composition for the treatment of viral infection |
| JP2003002989A (ja) | 2001-06-19 | 2003-01-08 | Toray Ind Inc | プリプレグ |
| CN100340283C (zh) | 2002-04-15 | 2007-10-03 | 山东哲夫 | 用于皮炎治疗的化妆水 |
| CN1332692C (zh) | 2002-04-15 | 2007-08-22 | 山东哲夫 | 用于皮炎治疗的饮用茶 |
| CN1316996C (zh) | 2002-12-26 | 2007-05-23 | 中国医科大学附属第一医院 | 治疗炎性肠病的复方青黛剂及制备方法 |
| KR20050077310A (ko) * | 2004-01-27 | 2005-08-02 | 주식회사 엘지생활건강 | 인디고 추출물을 이용한 모발, 눈썹 및 속눈썹 성장촉진제 |
| CN1586506A (zh) | 2004-06-29 | 2005-03-02 | 邹卫民 | 降白口服液 |
| JP5023317B2 (ja) | 2005-03-03 | 2012-09-12 | 国立大学法人弘前大学 | Ｉｖ型アレルギー反応抑制剤 |
| JP2007326855A (ja) * | 2006-05-11 | 2007-12-20 | Mitsubishi Gas Chem Co Inc | 新規配糖体 |
| CN101541340A (zh) * | 2006-11-24 | 2009-09-23 | 株式会社林原生物化学研究所 | 蓝草提取物粉末及其制造方法、以及该蓝草提取物粉末的用途 |
| CA2754961C (en) | 2009-03-11 | 2018-04-10 | Promedior, Inc. | Treatment and diagnostic methods for hypersensitive disorders |
| CN102247415B (zh) | 2010-05-21 | 2013-09-04 | 成都中医药大学 | 一种青黛炮制方法 |
| TWI438000B (zh) * | 2011-02-18 | 2014-05-21 | Galderma Res & Dev | 青黛之經油萃取的產物及其製備方法與用途 |
| TWI468169B (zh) | 2011-02-18 | 2015-01-11 | Galderma Res & Dev | 青黛之經油萃取的產物及其製備方法與用途 |
| EP2700406B1 (en) * | 2011-03-14 | 2017-10-11 | Sunstar Inc. | Method for producing indigo-plant leaf extract |
| US20140112945A1 (en) | 2011-06-17 | 2014-04-24 | Takeda Gmbh | Novel phthalazinone-pyrrolopyrimidinecarboxamide derivatives |
| CN102351863A (zh) | 2011-10-10 | 2012-02-15 | 南京泽朗医药科技有限公司 | 一种从菘蓝中提取青黛酮的方法 |
| KR20130071857A (ko) * | 2011-12-21 | 2013-07-01 | 원효정 | 쪽과 황칠나무 추출물을 유효성분으로 포함하는 물티슈 및 일회용 흡수제품과 이의 제조방법 |
| CN103766415A (zh) | 2012-10-17 | 2014-05-07 | 天津市中科健新材料技术有限公司 | 一种含壳聚糖的草本抗菌剂 |
| WO2014118040A1 (en) | 2013-01-29 | 2014-08-07 | Axel Brattstroem | Extract from indigo tinctoria for the topical treatment and prophylaxis of skin disorders |
| US20140243354A1 (en) * | 2013-02-22 | 2014-08-28 | Galderma Research & Development Snc | Combinations of indigo naturalis and berberine and uses thereof |
| AU2014223226A1 (en) | 2013-02-28 | 2015-09-03 | Precision Dermatology, Inc. | Topical formulations of corticosteroids with enhanced bioavailability |
| JP6161438B2 (ja) * | 2013-07-09 | 2017-07-12 | 日本甜菜製糖株式会社 | 脂肪蓄積抑制及び／又は脂肪蓄積量低減剤 |
| CN103992260A (zh) | 2014-05-29 | 2014-08-20 | 哈尔滨医科大学 | 一种从大青叶中提取靛玉红的方法 |
| CN104147309B (zh) * | 2014-08-13 | 2017-12-05 | 天津开发区天光高科技开发有限公司 | 一种盐藻素营养组合物及其制备方法 |
| KR20170133497A (ko) | 2015-04-09 | 2017-12-05 | 갈데르마 소시에떼아노님 | 인디고 내추럴리스로부터의 추출물 및 그의 제조 방법 |
| JP6803849B2 (ja) | 2015-04-09 | 2020-12-23 | ガルデルマ・ソシエテ・アノニム | インジゴナチュラリス又はインジゴ産生植物の抽出物を用いたアトピー性皮膚炎の処置 |
| BR112017021190B1 (pt) | 2015-04-09 | 2021-12-21 | Galderma Sa. | Uso de uma composição farmacêutica que compreende um extrato de indigo naturalis |
-
2016
- 2016-04-08 KR KR1020177032047A patent/KR20170133497A/ko not_active Withdrawn
- 2016-04-08 WO PCT/EP2016/057761 patent/WO2016162484A1/en not_active Ceased
- 2016-04-08 AU AU2016245203A patent/AU2016245203B2/en not_active Ceased
- 2016-04-08 SI SI201630166T patent/SI3209313T1/sl unknown
- 2016-04-08 HU HUE16717299A patent/HUE041308T2/hu unknown
- 2016-04-08 EP EP16717299.8A patent/EP3209313B1/en active Active
- 2016-04-08 JP JP2017552864A patent/JP6820273B2/ja not_active Expired - Fee Related
- 2016-04-08 CA CA2981624A patent/CA2981624A1/en not_active Abandoned
- 2016-04-08 ES ES16717299T patent/ES2709359T3/es active Active
- 2016-04-08 HR HRP20190088TT patent/HRP20190088T1/hr unknown
- 2016-04-08 SM SM20190054T patent/SMT201900054T1/it unknown
- 2016-04-08 BR BR112017021191-2A patent/BR112017021191B1/pt not_active IP Right Cessation
- 2016-04-08 DK DK16717299.8T patent/DK3209313T3/da active
- 2016-04-08 PT PT16717299T patent/PT3209313T/pt unknown
- 2016-04-08 TW TW105111116A patent/TWI732754B/zh not_active IP Right Cessation
- 2016-04-08 CN CN201680019978.XA patent/CN107427545A/zh active Pending
- 2016-04-08 RS RS20190131A patent/RS58304B1/sr unknown
- 2016-04-08 TR TR2019/01146T patent/TR201901146T4/tr unknown
- 2016-04-08 MX MX2017012595A patent/MX378168B/es unknown
- 2016-04-08 LT LTEP16717299.8T patent/LT3209313T/lt unknown
- 2016-04-08 EP EP18211851.3A patent/EP3482763A1/en not_active Withdrawn
- 2016-04-08 PL PL16717299T patent/PL3209313T3/pl unknown
-
2017
- 2017-05-11 US US15/592,893 patent/US9861673B2/en not_active Expired - Fee Related
- 2017-12-13 US US15/839,992 patent/US10251926B2/en active Active
-
2019
- 2019-01-25 CY CY20191100104T patent/CY1121187T1/el unknown
- 2019-03-28 US US16/367,405 patent/US10695391B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3209313T3 (da) | Et ekstrakt fra indigo naturalis og en fremgangsmåde til fremstilling af samme | |
| US11116811B2 (en) | Pharmaceutical composition comprising refined indigo naturalis extracts and the use thereof | |
| KR20090043115A (ko) | 감태에서 추출한 플로로탄닌을 함유하는 아토피 질환의치료 또는 예방용 조성물 | |
| WO2017016355A1 (zh) | 一种中药提取物及其制备方法与应用 | |
| CN101432009B (zh) | 预防性治疗和减轻变态反应性疾病 | |
| CN105726524A (zh) | 二苯庚烷类化合物在制备防治银屑病药物或食品中的应用 | |
| Xu et al. | Curcuma longa L. extract and residue prevent Alzheimer’s disease in mice by regulating microglia and TLR4/NF-κ B signaling pathway | |
| HK40004341A (en) | An extract from indigo naturalis and a process for preparing the same | |
| CN104447783B (zh) | 反柄灵芝酚a和b及其药物组合物与其在制药和食品中的应用 |